MedPath

Registration of Idarucizumab for Patients with IntraCranial Hemorrhage

Registration Number
NCT04062097
Lead Sponsor
University Hospital, Essen
Brief Summary

This multicenter, prospective, observational, non-interventional study investigates patients with intracranial hemorrhage under effective anticoagulation with dabigatran or vitamin-K antagonist (VKA). Routine data will be collected during hospitalization. Patients aged 18 years or older under effective therapy with dabigatran and symptomatic intracranial bleeding confirmed by cerebral imaging and treated with idarucizumab will be compared to patients under effective treatment with VKA at the time of onset of the intracranial bleeding. Ninety-five dabigatran patients who provided written informed consent for data transmission will be included. As control group retrospective and anonymized data of 285 VKA patients patients under VKA treatment and admitted to RIC-ICH study centers will be used. For each patient receiving idarucizumab, three patients with intracranial hemorrhage under effective treatment with VKA, will be included (retrospective) in the study. In addition, data of VKA patients will be transferred from the RASUNOA-PRIME and the "Erlanger Hirnblutungs-Register".

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
104
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
dabigatran-groupDabigatran Etexilate Oral Capsule [Pradaxa]Patients with the anticoagulating therapy dabigatran and onset of clinically symptomatic intracranial hemorrhage, that is treated with idarucizumab.
dabigatran-groupIdarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]Patients with the anticoagulating therapy dabigatran and onset of clinically symptomatic intracranial hemorrhage, that is treated with idarucizumab.
VKA-groupVitamin K antagonistPatients under effective treatment with VKA and with intracranial hemorrhage.
Primary Outcome Measures
NameTimeMethod
Intra-hospital mortality rateFrom study inclusion until hospital discharge or 30 days after index event, whichever came first.

Intra-hospital mortality rate

Secondary Outcome Measures
NameTimeMethod
Intracranial bleedingBetween 24 and 72 hours after initial CT.

Change in size/volume of \> 33% or ≥ 6.5 ml of the intracranial bleeding evaluated by first CT

Functional statusAt hospital discharge or 30 days after index event, whichever came first.

Functional status according to modified Rankin Scale (mRS). The scale runs from 0-6, running from perfect health without symptoms to death: 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead.

Change in National Institutes of Health Stroke Scale (NIHSS)At hospital admission, 24 hours after admission and 72 hours after admission.

Change in National Institutes of Health Stroke Scale (NIHSS) of ≥4 pts compared to initial NIHSS or worsening of NIHSS level of consciousness ≥1 point or increase of the volume of the intracranial bleeding or new intraventricular bleeding or death. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

Mortality rate7 and 30 days after index event.

Mortality rate

Stroke severity72 hours after hospital admission

Change in stroke severity by ≥4 points based on National Institutes of Health Stroke Scale (NIHSS). The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

Trial Locations

Locations (33)

Klinikum Schön Klinik Bad Aibling SE & Co. KG

🇩🇪

Bad Aibling, Germany

Hochtaunuskliniken GmbH

🇩🇪

Bad Homburg, Germany

Rhön Klinikum Campus Bad Neustadt

🇩🇪

Bad Neustadt An Der Saale, Germany

Vivantes Klinikum Auguste Viktoria

🇩🇪

Berlin, Germany

Vivantes Klinikum Neukölln

🇩🇪

Berlin, Germany

Vivantes Humboldt Klinikum

🇩🇪

Berlin, Germany

Evangelisches Klinikum Bethel gGmbH

🇩🇪

Bielefeld, Germany

Universitätsklinkum Bonn

🇩🇪

Bonn, Germany

Carl-Thiem-Klinikum Cottbus gGmbH

🇩🇪

Cottbus, Germany

Klinikum Allgemeines Krankenhaus Celle

🇩🇪

Celle, Germany

SHR Wald-Klinikum Gera GmbH

🇩🇪

Gera, Germany

Krankenhaus St. Elisabeth gGmbH

🇩🇪

Damme, Germany

Albert-Ludwigs-Universität Freiburg

🇩🇪

Freiburg, Germany

Georg-August-Universität Göttingen, Universitätsmedizin

🇩🇪

Göttingen, Germany

Klinikum Martha Maria

🇩🇪

Halle, Germany

Asklepios Klinik Wandsbek

🇩🇪

Hamburg, Germany

Asklepios Klinik Barmbek

🇩🇪

Hamburg, Germany

Universitätsklinikum Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

Klinikum Agatharied GmbH

🇩🇪

Hausham, Germany

Universitätsklinikum Heidelberg

🇩🇪

Heidelberg, Germany

BDH-Klinik Hessisch Oldendorf

🇩🇪

Hessisch Oldendorf, Germany

Universitätsklinikum Schleswig-Holstein, Campus Kiel

🇩🇪

Kiel, Germany

Universität Leipzig

🇩🇪

Leipzig, Germany

Klinikum Main-Spessart Lohr

🇩🇪

Lohr, Germany

Universitätsklinikum Schleswig-Holstein, Campus Lübeck

🇩🇪

Lübeck, Germany

Universitätsmedizin der Johannes-Guttenberg-Universität Mainz

🇩🇪

Mainz, Germany

Klinikum Vest Knappschaftskrankenhaus

🇩🇪

Recklinghausen, Germany

Klinikum Osnabrück

🇩🇪

Osnabrück, Germany

Klinikum Nordwest Krankenhaus Sande

🇩🇪

Sanderbusch, Germany

Klinikum der Landeshauptstadt Stuttgart gKAöR

🇩🇪

Stuttgart, Germany

Universitätsklinikum Tübingen

🇩🇪

Tübingen, Germany

Sana HANSE-Klinikum Wismar GmbH

🇩🇪

Wismar, Germany

Katholisches Klinikum Bochum gGmbH, St. Josef Hospital

🇩🇪

Bochum, Germany

© Copyright 2025. All Rights Reserved by MedPath